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A previously described system for modeling organ deformation using finite element analysis has
been extended to permit dose calculation. Using this tool, the calculated dose to the liver during
radiotherapy can be compared using a traditional static model ~STATIC!, a model including rigid
body motion ~RB!, and finally a model that incorporates rigid body motion and deformation ~RBD!.
A model of the liver, consisting of approximately 6000 tetrahedral finite elements distributed
throughout the contoured volume, is created from the CT data obtained at exhale. A deformation
map is then created to relate the liver in the exhale CT data to the liver in the inhale CT data. Six
intermediate phase positions of each element are then calculated from their trajectories. The coor-
dinates of the centroid of each element at each phase are used to determine the dose received. These
intermediate dose values are then time weighted according to a population-modeled breathing
pattern to determine the total dose to each element during treatment. This method has been tested
on four patient datasets. The change in prescribed dose for each patient’s actual tumor as well as a
simulated tumor of the same size, located in the superior, intermediate, and inferior regions of the
liver, was determined using a normal tissue complication model, maintaining a predicted probabil-
ity of complications of 15%. The average change in prescribed dose from RBD to STATIC for
simulated tumors in the superior, intermediate, and inferior regions are 4.0 ~range 2.1 to 5.3!, 23.6
~range 25.0 to 22.2!, and 214.5 ~range 227.0 to 210.0! Gy, respectively. The average change in
prescribed dose for the patient’s actual tumor was 20.4 Gy ~range 24.1 to 1.7 Gy!. The average
change in prescribed dose from RBD to RB for simulated tumors in the superior, intermediate, and
inferior regions are 20.04 ~range 22.4 to 2.2!, 0.2 ~range 21.5 to 1.9!, and 3.9 ~range 0.8 to 7.3!
Gy, respectively. The average change in the prescribed dose for the patient’s actual tumor was 0.7
Gy ~range 0.2 to 1.1 Gy!. This patient sampling indicates the potential importance of including
deformation in dose calculations. © 2003 American Association of Physicists in Medicine.
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Organ movement and its impact on treatment dose has been
the subject of significant research effort over the past few
years. While progress has been made in evaluating move-
ment using a rigid body model, the impact of deformation on
dose calculation is an area of study that is still in its infancy.
Several studies have investigated the effects of motion on
the calculated dose distribution. For example, Killoran et al.
used Monte Carlo to simulate the effect of variation in over-
all tumor position and introduced the concept of Probability
of Prescription Dose to determine nonuniform beam margins
that lead to a reduction in dose to critical organs.1 Mageras
et al. used multiple CT scans to estimate the uncertainty in
dose delivery and determine confidence limit dose volume
histograms ~DVH!.2
Previous studies have shown that motion of the liver as-
sociated with breathing typically ranges from 1–3 cm.3 Stan-
dard treatment planning assumes that the liver is not moving
but includes a treatment margin to account for the breathing290 Med. Phys. 30 3, March 2003 0094-2405Õ2003Õ30motion observed under fluoroscopy. Ten Haken et al. dem-
onstrated that by eliminating organ motion due to breathing,
the prescribed dose to focal liver cancer, for a specified nor-
mal tissue complication probability ~NTCP! risk, was in-
creased by 6–8 Gy.4 Obtaining a planning CT scan at end
exhale and using asymmetric margins to account for breath-
ing motion has also permitted an increased dose to be deliv-
ered to focal liver cancer.5
Lujan et al. developed a convolution model for evaluating
the impact of ventilatory movement on the dose distribution
to the liver.6 The convolution calculations demonstrated
changes in point dose up to 26% when compared to static
dose calculations. This model assumed that the liver moved
as a rigid body, however, and motion along other cardinal
axes was ignored.
Evidence of liver deformation during breathing has
evolved over the past few years. Miller7 described the liver
using a viscoelastic model, based on original data from
Melvin et al.8 Yan et al. showed an example of liver defor-2903Õ290Õ6Õ$20.00 © 2003 Am. Assoc. Phys. Med.
291 Brock et al.: Inclusion of organ deformation 291mation and described a potential infrastructure for incorpo-
rating deformation in treatment planning evaluation.9 Kruse
et al. performed experiments on pig livers, and documented
the elasticity.10 Balter et al. demonstrated potential compres-
sion of the liver during breathing using data from
fluoroscopy.3 We have recently demonstrated liver deforma-
tion between inhale and exhale states using CT models, and
described a method for determining the deformation that oc-
curs from the exhale to the inhale state.11 The method uses
finite element analysis ~FEA! to describe the liver volume as
tetrahedral elements. Using a linear elastic model, the trans-
formation for each element is determined using boundary
conditions applied to the exhale model to create the shape
and position of the inhale model.
The purpose of this study is to investigate the importance
of including deformation in dose calculations. A comparison
of the calculated dose to the liver is made between the stan-
dard static planning method ~STATIC!, the inclusion of rigid
body motion only in the inferior-superior ~IS! direction ~RB!,
and including motion in all three directions as well as ac-
counting for a change in shape due to the deformation that
occurs during breathing ~RBD!. A simulated tumor is used to
determine the dependence of the tumor location on the influ-
ence that deformation has in dose calculations.
II. METHODS AND MATERIALS
A. Patient data collection
For this preliminary investigation, data were acquired
from four patients. Under a protocol approved by the Internal
Review Board at the University of Michigan, computed to-
mography ~CT! scans were acquired at inhale and exhale
breath-hold states. The patients’ breath was held either vol-
untarily (n51) or using active breathing control (n53).20
The inhale CT scan was obtained at the end of inhale during
normal breathing ~i.e. not deep inhale!. For voluntary breath
hold scans, the patient was coached to hold their breath at the
end of inhale during normal breathing. For patients’ whose
breath was held using active breathing control, the breath-
hold was triggered at end inhale, as determined during nor-
mal breathing preceding the breath-hold. All scans were ac-
quired using a helical CT scanner ~CT/I, General Electric,
Milwaukee WI! using a 3 mm aperture and a pitch of 2. Both
inhale and exhale CT scans were obtained in the same way to
eliminate any offset between the two datasets due to patient
movement ~the total time for both scans ;3–5 min!. Move-
ment of the diaphragm during normal breathing ~observed
from CT data! ranged from 1.5–2.4 cm. Similar SI move-
ment was seen on fluoroscopy during free breathing.
B. Dose matrix creation
The attending physician contoured the liver tumor and a
plan was created for radiation treatment based on the exhale
CT-based patient model, using an in-house three-dimensional
treatment planning system ~UMPLAN!. Planning target vol-
ume ~PTV! margins included an isotropic 5 mm expansion
for setup error, an inferior margin for the patient-specificMedical Physics, Vol. 30, No. 3, March 2003range of diaphragm movement due to breathing, and an ad-
ditional 3 mm superior expansion for reproducibility of the
exhale state.5 For this study, three simulated tumors were
also created in the exhale patient dataset. The size of the
simulated tumors varied slightly between individual patients
to accommodate complete inclusion within the inferior re-
gion of the liver. Simulated tumors ranged in volume from
59 to 75 cm3. The simulated tumors were placed in the su-
perior, intermediate, and inferior regions of the liver. Simu-
lated tumors are shown for one case in Fig. 1. Tumors in the
FIG. 1. Simulated tumor ~black! and PTV ~gray! in the superior ~a!, inter-
mediate ~b!, and inferior ~c! regions of the liver ~lines!.
292 Brock et al.: Inclusion of organ deformation 292intermediate region were placed midway within the inferior–
superior extent of the liver so that the GTV was completely
encompassed within the boundaries of the liver, although the
PTV expansions were permitted to be outside the liver. The
simulated tumors allowed an investigation into the depen-
dence of deformation-induced dosimetric changes on the lo-
cation of the tumor within the liver.
Treatment plans were created for each of the three simu-
lated tumors, adhering to the same criteria as the original
plan for the actual tumor ~coverage of the PTV with 95% or
greater dose, constraints on spinal cord dose, and attempts to
minimize dose–volume involvement of a normal liver!. Dose
distributions were calculated on the exhale and inhale CT
datasets. The dose matrix had an isotropic spatial resolution
of 3 mm.
C. Dose summation method
As described previously11 the liver model is comprised of
6000 tetrahedral elements of varying size and shape. An ex-
ample of one liver comprised of such elements is shown in
Fig. 2. The volume of each element was computed as well as
the location of the centroid. A deformation map was created
using either manual or more automated techniques.12 Using
this deformation map, the displacement of each node that
makes up each element in the finite element model was de-
termined. This displacement was then split into six uniform
increments to simulate phases of the breathing cycle. Phase 0
corresponded to the exhale position and phase 1 corre-
sponded to the inhale position. The size and centroid location
of each element was then determined for each intermediate
phase.
The inhale and exhale CT models provided two maps of
density at the extremes of normal breathing from which the
dose was calculated. While an ideal system for calculating
the dose to the intermediate phases of breathing would gen-
erate density maps for these states, an approximation was
FIG. 2. Tetrahedral mesh of the liver volume.Medical Physics, Vol. 30, No. 3, March 2003developed to use the existing data and to modulate the
weight of dose calculations from the exhale toward the in-
hale model as breathing progresses.
The location of the centroid of each element was used to
look up the dose at that point in the dose matrix. The relative
dose value for a given element and breathing phase was cal-
culated as
Df~x ,y ,z !5DE~x ,y ,z !f1DI~x ,y ,z !~12f!, ~1!
where x, y, z are the element coordinates, Df is the relative
dose at phase f ~without considerations of time weighting!,
and DE and DI are the calculated dose values from the ex-
hale and inhale CT density grids, respectively. f varies from
0 ~exhale! to 1 ~inhale! in increments of 0.2.
Time weighting was then applied to the relative dose at
each phase for each element location using information gath-
ered via fluoroscopy on a population of patients previously
studied.5 The time weighting factors are shown in Table I.
An average volume for each element was also created by
time weighting the volume of each element according to the
same method described in Table I. This process provided
appropriate volume weighting for each element in the con-
struction of dose volume histograms.
D. Planning methods
Three calculation methods were compared. The first was
the standard static plan ~STATIC!. The static plan only in-
cluded the data from phase 0, the exhale position.
The second method included rigid body ~RB! motion in
the inferior superior direction only. The motion in the infe-
rior superior ~IS! direction was determined from the differ-
ence in the position of the diaphragm on the CT scan. This
displacement was then assigned as the displacement for ev-
ery node in the liver in the IS direction. The lateral and AP
displacements were set to zero.
The third method included rigid body plus deformation
~RBD!. This method took advantage of all data obtained
from deformation modeling, including varying displace-
ments in all three directions for all elements in the model.
E. Comparison method
The three planning methods were then compared via ob-
servation of dose volume histograms ~DVHs! of the normal
liver tissue @liver minus gross tumor volume ~GTV!#, as well
as evaluations of effective volume (Veff)13 of the normal liver
volume and change in prescribed dose for a specified normal
tissue complication probability ~NTCP! risk,14 calculated us-
TABLE I. Relative time weights.
f Time weight
0 ~exhale! 0.48
0.2 0.13
0.4 0.09
0.6 0.08
0.8 0.10
1.0 ~inhale! 0.12
293 Brock et al.: Inclusion of organ deformation 293ing the Lyman model15 with parameters m50.12, TD~1!546
Gy, and n50.97.16 While the current focal liver protocol at
the University of Michigan limits the prescribed dose to the
tumor to 90 Gy, this limitation was ignored for the simulated
tumors to permit comparisons in the event that higher doses
were permissible at a 15% NTCP risk level. Maximum point
dose differences between the three methods were also deter-
mined. The planning methods were compared for each of the
three simulated tumor positions as well as for the actual pa-
tient tumor.
FIG. 3. DVHs for a simulated tumor in the superior ~a!, intermediate ~b!, and
inferior ~c! region of the liver.Medical Physics, Vol. 30, No. 3, March 2003III. RESULTS
A. Dose differences
Differences in calculated dose points were observed be-
tween all three methods of dose calculation, STATIC, RB,
and RBD. Point dose differences up to 44% were seen be-
tween the STATIC and RBD plans and up to 42% between
the RBD and RB plans. The largest point dose differences
were seen along beam edges, in areas of high dose gradients.
STATIC, RB, and RBD cumulative DVHs of the normal
liver tissue are shown for simulated tumors in the superior,
intermediate, and inferior regions of the liver in Fig. 3, re-
spectively, for one example case.
B. Change in prescribed dose—Simulated tumors
Changes in the tumor prescribed dose, with a liver iso-
NTCP of 15%, are shown in Table II for the simulated tu-
mors. The average change in prescribed dose between the
RBD and STATIC calculations for tumors in the superior,
intermediate, and inferior regions of the liver are 4.0 ~range
2.1 to 5.3!, 23.6 ~range 25.0 to 22.2!, and 214.5 ~range
227.0 to 210.0! Gy, respectively. The average change in
prescribed dose between the RBD and RB calculations for
tumors in the superior, intermediate, and inferior regions of
the liver are 20.04 ~range 22.4 to 2.2!, 0.2 ~range 21.5 to
1.9!, and 3.9 ~range 0.8 to 7.3! Gy, respectively. The average
dose that could be prescribed with an iso-NTCP of 15%, for
all patients and all three calculation methods, to the simu-
lated tumors in the superior, intermediate, and inferior re-
gions of the liver, was 84.6, 92.7, and 157.0 Gy.
Changes in the Veff of normal liver tissue are shown in
Table III for the simulated tumors. The average change in
Veff between the RBD and STATIC calculations for tumors in
the superior, intermediate, and inferior regions of the liver
are 22.3% ~range 23.1 to 21.4%!, 1.7% ~range 1.0 to
2.2%!, and 2.1% ~range 1.7 to 2.5%!, respectively. The av-
erage change in Veff between the RBD and RB calculations
for tumors in the superior, intermediate, and inferior regions
of the liver are 0.1% ~range 21.2 to 1.5%!, 20.1% ~range
20.9 to 0.6%!, and 20.6% ~range 21.0 to 20.2%!, respec-
tively.
C. Change in prescribed dose—Actual patient tumors
Changes in the tumor prescribed dose, with a liver iso-
NTCP of 15%, are shown in Table IV for the actual patient
tumors. The average change in prescribed dose between the
RBD and STATIC calculations for the actual tumors is 20.4
~range 24.1 to 1.7! Gy. The average change in prescribed
TABLE II. Change in prescribed dose ~Gy! for NTCP515% for simulated
tumors.
Superior Intermediate Inferior
AVG Range AVG Range AVG Range
RBD-STATIC 4.0 2.1–5.3 23.6 25.0–22.2 214.5 227–210
RBD-RB 20.04 22.4–2.2 0.2 21.5–1.9 3.9 0.8–7.3
294 Brock et al.: Inclusion of organ deformation 294dose between the RBD and RB calculations for the actual
tumors is 0.7 ~range 0.2 to 1.1! Gy. The average prescribed
dose to the actual tumors was 62.3 Gy.
Changes in the Veff of normal liver tissue are shown in
Table V for the actual patient tumors. The average change in
Veff between the RBD and STATIC calculations for the ac-
tual tumor is 0.2% ~range 22.0 to 3.3%!. The average
change in Veff between the RBD and RB calculations for the
actual tumors is 20.7% ~range 20.9 to 20.4%!.
IV. DISCUSSION
We have demonstrated an infrastructure to calculate the
dose to a deforming organ. Preliminary results show that the
inclusion of deformation can make a substantial impact in
the prescribed dose to liver tumors, compared to a static dose
calculation and calculations including rigid body motion in
the inferior–superior direction only. A dose difference depen-
dence on tumor location was observed. Compared to the
RBD calculation, the STATIC calculation tended to under-
prescribe to tumors in the superior region of the liver and
overprescribe to tumors in the intermediate and inferior re-
gions of the liver, as expected for those patients planned at
exhale.6 The tumors in the intermediate region of the liver
behaved more like the tumors in the inferior region, because
some of the PTV extended outside ~below! the liver volume,
in a similar manner to tumors in the inferior region of the
liver.
Compared to RBD calculations, the RB calculations
tended to underprescribe to tumors in the inferior region of
the liver. Trends were not seen, between the RBD and RB
calculations, for tumors in the superior and intermediate re-
gions of the liver. However, clinically significant differences
~defined as a change in the prescribed dose of one fraction,
1.5 Gy, or greater! were seen in two out of four cases for
simulated tumors in the superior and intermediate regions of
the liver.
The volume of normal tissue treated to a high dose for
simulated tumors in the inferior region of the liver is very
small, resulting in relatively large changes in prescribed
doses ~the last column of Table II!. This is a consequence of
the small effective volume irradiated and the fact that a small
TABLE III. Change in effective volume ~%! for simulated tumors.
Superior Intermediate Inferior
AVG Range AVG Range AVG Range
RBD-STATIC 22.3 23.1–1.4 1.7 1.0–2.2 2.1 1.7–2.5
RBD-RB 0.1 21.2–1.5 20.1 20.9–0.6 20.6 21.0–20.2
TABLE IV. Change in prescribed dose ~Gy! for NTCP515% for actual
tumor.
AVG Range
RBD-STATIC 20.4 24.1–1.7
RBD-RB 0.7 0.2–1.1Medical Physics, Vol. 30, No. 3, March 2003change in Veff can lead to large changes in the normalization
dose in this iso-NTCP region.14 These high doses were only
used to exemplify the simulated difference in the prescribed
dose for tumors in the inferior region of the liver. Current
focal liver protocols at the University of Michigan have a
dose limit of 90 Gy.
One limitation of this method is the lack of intermediate
density grids for dose calculations. Ideally six CT scans
would be obtained at the six phases of the breathing cycle,
where the dose is calculated. However, the accuracy in ob-
taining a CT scan at a precise point of mid-ventilation is
uncertain. Use of active breathing control devices offers
some potential, although accuracy at mid-ventilation posi-
tions has not yet been investigated.
These findings demonstrate the potential for deformation
to impact the calculation of dose to intrahepatic targets, po-
tentially to the extent that clinical decisions about the treat-
ment regime and dose would be impacted. A larger scale
study is warranted in order to determine whether any trends
can be established as guidelines for the necessity of includ-
ing deformation in treatment planning for the liver. A more
complete understanding of physiologic processes such as
breathing and their impact on delivered doses will aid clinics
in making decisions related to not only treatment dose pre-
scriptions, but also the relative gains of interventional tech-
nology such as gating,17,18 active breathing control,19,20 and
image guidance.21,22
ACKNOWLEDGMENTS
This work was supported in part by NIH Grant No. P01-
CA59827. The authors would like to thank Robin Marsh for
her assistance with treatment planning and Marc Kessler for
his valuable advice. The authors would also like to thank
Mihaela Rosu for her assistance with NTCP calculations.
a!Electronic mail: kkbrock@umich.edu
1 J. H. Killoran, H. K. Kooy, D. J. Gladstone, F. J. Welte, and C. J. Beard,
‘‘A numerical simulation of organ motion and daily setup uncertainties:
implications for radiation therapy,’’ Int. J. Radiat. Oncol., Biol., Phys. 37,
213–221 ~1997!.
2 G. S. Mageras, G. H. Kutcher, S. A. Leibel, M. J. Zelefsky, E. Melian, R.
Mohan, and Z. Fuks, ‘‘A method of incorporating organ motion uncer-
tainties into three-dimensional conformal treatment plans,’’ Int. J. Radiat.
Oncol., Biol., Phys. 35, 333–342 ~1996!.
3 J. M. Balter, L. A. Dawson, S. Kazanjian, C. McGinn, K. K. Brock, T. S.
Lawrence, and R. K. Ten Haken, ‘‘Determination of ventilatory liver
movement via radiographic evaluation of diaphragm position,’’ Int. J.
Radiat. Oncol., Biol., Phys. 51, 267–270 ~2001!.
4 R. K. Ten Haken, J. M. Balter, L. H. Marsh, J. M. Robertson, and T. S.
Lawrence, ‘‘Potential benefits of eliminating planning target volume ex-
pansions for patient breathing in the treatment of liver tumors,’’ Int. J.
Radiat. Oncol., Biol., Phys. 38, 613–617 ~1997!.
5 J. M. Balter, K. L. Lam, C. J. McGinn, T. S. Lawrence, and R. K. Ten
Haken, ‘‘Improvement of CT-based treatment-planning models of ab-
TABLE V. Change in effective volume ~%! for actual tumor.
AVG Range
RBD-STATIC 0.2 22.0–3.3
RBD-RB 20.7 20.9–20.4
295 Brock et al.: Inclusion of organ deformation 295dominal targets using static exhale imaging,’’ Int. J. Radiat. Oncol., Biol.,
Phys. 41, 939–943 ~1998!.
6 A. E. Lujan, E. W. Larsen, J. M. Balter, and R. K. Ten Haken, ‘‘A method
for incorporating organ motion due to breathing into 3D dose calcula-
tions,’’ Med. Phys. 26, 715–720 ~1999!.
7 K. Miller, ‘‘Constitutive modeling of abdominal organs,’’ J. Biomech. 33,
367–373 ~2000!.
8 J. W. Melvin, R. L. Stalnaker, and V. L. Roberts, ‘‘Impact injury mecha-
nisms in abdominal organs,’’ SAE Trans. 730968, 115–126 ~1973!.
9 D. Yan and D. Lockman, ‘‘Organ/patient geometric variation in external
beam radiotherapy and its effects,’’ Med. Phys. 28, 593–602 ~2001!.
10 S. A. Kruse, J. A. Smith, A. J. Lawrence, M. A. Dresner, A. Manduca, J.
F. Greenleaf, and R. L. Ehman, ‘‘Tissue characterization using magnetic
resonance elastography: preliminary results,’’ Phys. Med. Biol. 45, 1579–
1590 ~2000!.
11 K. K. Brock, S. J. Hollister, L. A. Dawson, and J. M. Balter, ‘‘Technical
Note: Creating a 4-Dimensional model of the liver using finite element
analysis,’’ Med. Phys. 29, 1403–1405 ~2002!.
12 C. R. Meyer, J. L. Boes, B. Kim, P. H. Bland, K. R. Zasadny, P. V. Kison,
K. Koral, K. A. Frey, and R. L. Wahl, ‘‘Demonstration of accuracy and
clinical versatility of mutual information for automatic multimodality im-
age fusion using affine and thin-plate spline warped geometric deforma-
tions,’’ Med. Image Anal 3, 195–206 ~1997!.
13 G. J. Kutcher and C. Burman, ‘‘Calculation of complication probability
factor for nonuniform normal tissue irradiation: The effective volume
method,’’ Int. J. Radiat. Oncol., Biol., Phys. 16, 1623–1630 ~1989!.
14 R. K. Ten Haken, M. K. Martel, M. L. Kessler, M. B. Hazuka, T. S.
Lawrence, J. M. Robertson, A. T. Turrisi, and A. S. Lichter, ‘‘Use of Veff
and iso-NTCP in the implementation of dose escalation protocols,’’ Int. J.
Radiat. Oncol., Biol., Phys. 27, 689–695 ~1993!.Medical Physics, Vol. 30, No. 3, March 200315 J. T. Lyman, ‘‘Complication probability as assessed from dose-volume
histograms,’’ Radiat. Res. 104, s13–s19 ~1985!.
16 L. A. Dawson, D. Normelle, J. M. Balter, C. J. McGinn, T. S. Lawrence,
and R. K. Ten Haken, ‘‘Analysis of radiation induced liver disease using
the Lyman NTCP model,’’ Int. J. Radiat. Oncol., Biol., Phys. 53, 810–
821 ~2002!.
17 H. D. Kubo and B. C. Hill, ‘‘Respiration gated radiotherapy treatment: A
technical study,’’ Phys. Med. Biol. 41, 83–91 ~1996!.
18 E. C. Ford, G. S. Mageras, E. Yorke, K. E. Rosenzweig, R. Wagman, and
C. C. Ling, ‘‘Evaluation of respiratory movement during gated radio-
therapy using film and electronic portal imaging,’’ Int. J. Radiat. Oncol.,
Biol., Phys. 52, 522–531 ~2002!.
19 J. W. Wong, M. B. Sharpe, D. A. Jaffray, V. R. Kini, J. M. Robertson, J.
S. Stromberg, and A. A. Martinez, ‘‘The use of active breathing control
~ABC! to reduce margin for breathing motion,’’ Int. J. Radiat. Oncol.,
Biol., Phys. 44, 911–919 ~1999!.
20 L. A. Dawson, K. K. Brock, S. Kazanjian, D. Fitch, C. J. McGinn, T. S.
Lawrence, R. K. Ten Haken, and J. Balter, ‘‘The reproducibility of organ
position using active breathing control ~ABC! during liver radiotherapy,’’
Int. J. Radiat. Oncol., Biol., Phys. 51, 1410–1421 ~2001!.
21 H. Shirato, S. Shimizu, K. Kitamura, T. Nishioka, K. Kagei, S. Hash-
imoto, H. Aoyama, T. Kunieda, N. Shinohara, H. Dosaka-Akita, and K.
Miyasaka, ‘‘Four-dimensional treatment planning and fluoroscopic real-
time tumor tracking radiotherapy for moving tumor,’’ Int. J. Radiat. On-
col., Biol., Phys. 48, 435–442 ~2000!.
22 K. Kitamura et al., ‘‘Registration accuracy and possible migration of in-
ternal fiducial gold marker implanted in prostate and liver treated with
real-time tumor-tracking radiation therapy ~RTRT!,’’ Radiother. Oncol.
62, 275–281 ~2002!.
